Formulation and Drug Delivery

Catalent to Manufacture Drug Substance for AstraZeneca’s COVID-19 Vaccine Candidate

August 24, 2020

Catalent will manufacture drug substance for AZD1222 at its Harmans, MD facility.

Novavax’s COVID-19 Vaccine Candidate Enters into Phase II Clinical Trials

August 24, 2020

The Phase II trial is a randomized, placebo-controlled, observer-blinded study that will include patients aged 18 to 84 years.

EC Reaches Agreement with AstraZeneca on Purchase of COVID-19 Vaccine

August 20, 2020

EC finalizes agreement to purchase millions of doses of AstraZeneca's COVID-19 vaccine.

Novavax Signs Term Sheet with UK Gov for COVID-19 Vaccine Doses

August 20, 2020

Novavax has signed an agreement with the UK government for 60 million doses of a COVID-19 vaccine and a Phase III clinical trial.

Expanding Options for Vaccine Packaging

August 19, 2020

Plastic primary packaging could help prevent supply chain shortages associated with high demand for COVID-19 vaccines.

Cadila Pharmaceuticals Launches Biosimilar Rituximab

August 13, 2020

The company has launched its biosimilar rituximab, Ritucad, for the Indian market.

Novavax Collaborates with SK bioscience for COVID-19 Vaccine Candidate

August 13, 2020

SK bioscience will manufacture the vaccine antigen component for use in the final drug product at its vaccine facility in Andong L-house, South Korea.

US Government Awards Moderna $1.5 billion for COVID-19 Vaccine Candidate

August 13, 2020

In combination with BARDA’s previous award, the commitment for early access to Moderna’s vaccine candidate has now reached to up to $2.48 billion.

Henlius and Accord Healthcare Receive European Approval for Biosimilar Trastuzumab

August 13, 2020

The companies received approval from the EC for Zercepac (HLX02), a biosimilar referencing Roche’s originator biologic, Herceptin (trastuzumab).

CHMP Gives Positive Opinion on Centus Biotherapeutics’ Bevacizumab Biosimilar

August 13, 2020

The committee has given a positive opinion on the biosimilar bevacizumab for several cancer indications.